Treating Alopecia Areata: Where are we at the end of 2020?
Treating Alopecia Areata: Where are we at the end of 2020? Anthony Gilding, Science and Research Communication at CANAAF Alopecia Areata (AA) was first clinically described in 1817 by Dr. Thomas Bateman as bald patches that were mainly circular. 203 years later, Alopecia Areata is recognized as an autoimmune disorder that causes varying
Long Term use of JAK Inhibitors (CTP-543) Shows Promising Results In CoNCERT Pharmaceuticals Study
Long Term use of JAK Inhibitors (CTP-543) Shows Promising Results In CoNCERT Pharmaceuticals Study Anthony Gilding, Science Communication at CANAAF CANAAF is very pleased to announce this exciting data presented by CoNCERT Pharmaceuticals at the 29th European Academy of Dermatology and Venereology (EADV) Virtual Congress. The data showed that, as with the previous
Burden of Illness in Alopecia Areata: A Cross-Sectional Online Survey Study
Alopecia Areata is a particularly distressing condition. The hair loss faced by patients is unexpected, and often rapid, leaving them feeling hopeless and vulnerable. Given how much we associate our identity with how we look, patients often feel that they have lost their sense of identity when they lose their hair. Though the
Journals with Alopecia Research
For those of you looking for scientific updates, here are a list of journals that publish alopecia research. Journal of the American Academy of Dermatology Journal of the American Medical Association - Dermatology Dermatologic Therapy Journal of Investigative Dermatology The New England Journal of Medicine Journal of Dermatological Science Australasian Journal
Arena Pharmaceuticals Announces First Subject Dosed in Phase 2 Trial Evaluating Etrasimod in Alopecia Areata
On September 1st, 2020, Arena Pharmaceuticals announced that the first subject has been dosed in Phase 2 of their trial evaluating a drug called Etrasimod, a Sphingosine-1-phosphate (S1P) Receptor Modulator for the treatment of moderate-to-severe Alopecia Areata. This clinical trial is a randomized, placebo-controlled trial, meaning that 36 subjects will be chosen randomly to
CSPA Survey: Access to Dermatology Care
The Canadian Skin Patient Alliance (CSPA) is conducting a survey on the impact of COVID-19 on access to dermatology care. Please take a moment to fill out the survey by clicking the link below: Take Survey Learn more by visiting the CSPA website and Facebook page.
Watch Dr. Donovan’s update from 2020 and learn about recent advancements in alopecia research.